Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
8,253 people get TEVA articles and Market Currents by email alert.
Get email alerts on TEVA »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
Business Wire (Tue, 10:35AM)
-
-
-
-
-
-
-
-
-
-
Business Wire (May 8, 2013)
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
Teva's CEO Reviews Management Succession (Transcript)Tue, Jan 3, 2012
-
Teva CEO Discusses Q4 2010 Results - Earnings Call TranscriptTue, Feb 8, 2011 • 1 Comment
-
Teva Pharmaceutical Industries Limited Q2 2010 Earnings Call TranscriptTue, Jul 27, 2010 • 1 Comment
-
Business Wire (Tue, 10:35AM)
-
at CNBC.com (May 9, 2013)
-
at CNBC.com (May 8, 2013)
-
Business Wire (May 8, 2013)
-
Business Wire (May 2, 2013)
-
at CNBC.com (Apr 26, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 23, 2013)
-
at CNBC.com (Apr 11, 2013)
-
Business Wire (Apr 9, 2013)
-
Business Wire (Apr 8, 2013)
-
Business Wire (Apr 8, 2013)
TEVA vs. ETF Alternatives
Company Description
Teva Pharmaceutical Industries Limited (“Teva”) is a global pharmaceutical company that develops, produces and markets generic drugs in all major therapeutic categories. We are the leading generic drug company in the world – with the leading position in the U.S. (in terms of both value and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 8, 9:11 AM Alexza Pharmaceuticals (ALXA) comes off trading halt, now up 52% premarket following the license deal with Teva (TEVA +0.3% premarket). The conference call discussing the matter is underway. 3 Comments [Breaking News, Healthcare, On the Move]
- Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
- Monday, April 29, 10:28 AM Biogen Idec (BIIB +4.9%) gains this morning after giving an update on Tecfidera prescription performance. According to data, the drug has already garnered nearly 8% of the multiple sclerosis market through the week ended April 19, with prescriptions up 120% over the prior week. By comparison, Novartis' (NVS) Gilenya saw a market share drop to 6%. RBC sees performance on track to meet quarterly sales expectations. Comment! [Healthcare, On the Move]
- Friday, April 12, 12:22 PM Generic giant Teva Pharmaceuticals (TEVA -2%) slides today after CNBC's Jim Cramer recommended selling the stock earlier, as the company appears to be underperforming its peers. Cramer also warned that the looming patent expiry for its MS treatment Copaxone, which accounts for 20% of TEVA's sales and is set to expire in 2015, makes a ripe target for other generic manufacturers. 5 Comments [Healthcare, On the Move]
- Friday, April 5, 8:01 AM Antares Pharma (ATRS) gets a Notice of Allowance from the U.S. Patent Trade Office regarding the company's patent application for the VIBEX QuickShot. ATRS said Thursday that the first shipment of the auto-injector devices will be on their way to Teva (TEVA) by the end of Q1. Shares +2% premarket. 1 Comment [Healthcare, On the Move]
- Thursday, April 4, 4:00 PM Synthetic Biologics (SYN +4.3%), which was trading lower on the session, jumps after saying a patent issued to the University of California "includes claims to the use of [the company's] drug candidate Trimesta in combination" with Copaxone, Teva's (TEVA -0.8%) annual $14B selling multiple sclerosis drug. 1 Comment [Healthcare, On the Move]
- Wednesday, March 27, 4:12 PM Shares of Teva (TEVA -1.2%) close lower today on the back of Biogen's (BIIB +3%) earlier announcement of FDA approval for its MS capsule Tecfidera. Earlier in the week, TEVA had announced its own successful results from Phase III testing for its Multiple Sclerosis drug Laquinimod. Comment! [Healthcare, Global & FX, On the Move]
- Tuesday, February 12, 1:46 PM Shares of Bristol-Myers (BMY -0.7%) slide after a federal judge rules a U.S. patent for its hepatitis B treatment Baraclude is invalid, saying there's clear and convincing evidence that a key claim in the patent is invalid due to obviousness. The ruling opens the door to Teva Pharmaceutical (TEVA +0.4%) selling a competing generic copy. BMY says it's disappointed in the ruling and plans to appeal. Comment! [Healthcare, On the Move]
- Friday, February 8, 1:56 PM Teva Pharmaceutical (TEVA +2.3%) shrugs off a downgrade to Hold at Canaccord to trade higher today. The company has been creeping higher since posting a less-than-stellar Q4 earnings report yesterday morning, perhaps in part due to comments during its conference call that sales of its MS drug Copaxone rose by 14% to $1.1B. Read more here: Earnings Call Transcript. Comment! [On the Move, Healthcare, Earnings]
- Tuesday, December 4, 2012, 8:24 AM Galena (GALE) soars 17.2% after signing a deal with Teva (TEVA) for the commercialization of its NeuVax breast cancer treatment in Israel. While financial terms weren't disclosed, Teva will make significant royalty payments to Galena on future sales. Israel will be the location of at least four sites for Phase 3 trials of NeuVax. Comment! [On the Move, Healthcare]
- Friday, November 30, 2012, 7:09 AM Teva Pharmaceutical (TEVA) forecasts 2013 EPS of $4.85-$5.15 against Street expectations for $5.63. Total revenue is expected at $19.5B-$20.5B. Shares -5.5% premarket. (PR) 2 Comments [Healthcare, On the Move, Breaking News]
- Wednesday, November 28, 2012, 12:53 PM Rexahn Pharmaceuticals (RNN +9%) trades higher after the company said that Teva Pharmaceutical (TEVA -0.6%) will provide an additional $750K in funding to the company. Pursuant to the terms of an earlier agreementl, TEVA will purchase RNN's common stock at 120% of its closing price on the last trading day preceding the closing. TEVA has also agreed to commit additional research funding for development of RX-3117, a potential treatment for solid tumors including colon, lung and pancreatic cancers, and will retain the right to file the Investigational New Drug application with the FDA. 2 Comments [Healthcare, On the Move]
- Tuesday, November 27, 2012, 3:00 PM Teva Pharmaceuticals (TEVA +0.9%) agrees to delay the introduction of generic versions of two Gilead (GILD -0.9%) HIV drugs, Truvada and Viread, until June 1 or until a judge rules on the patent fight between the two companies. GILD sued TEVA in 2008 and again in 2010, claiming its FDA applications to make HIV drugs infringed four of its patents. The complaints also listed the HIV drug Atripla, which wasn’t cited in today’s filing. Comment! [Healthcare, On the Move]
- Thursday, November 15, 2012, 8:28 AM Amarin (AMRN) +9% following a report that Teva (TEVA +0.7%) is leading the race to acquire the Irish biotech, which has a market cap of $1.6B, with AstraZeneca (AZN +0.4%) also in the hunt. Teva recently said it wasn't intending to make any major acquisitions, while it's also due to unveil a long-term overhaul in December. 3 Comments [Healthcare, On the Move, M&A]
- Wednesday, October 3, 2012, 3:35 PM The FDA has withdrawn approval of Impax (IPXL -1%) and Teva's (TEVA -0.5%) Budeprion XL 300 mg, saying it's reviewed new data that indicates it's not therapeutically equivalent to Wellbutrin XL 300 mg. Both companies have stopped shipping the product and are issuing detailed information to their customers. The FDA added that its announcement does not affect the Impax/Teva Budeprion 150 mg product or generic Budeprion products made by other manufacturers. Comment! [Healthcare, Global & FX, On the Move]
- Thursday, September 6, 2012, 1:36 PM Perrigo (PRGO +1.6%) files an Abbreviated New Drug Application with the FDA for albuterol sulfate HFA inhalation aerosol, a generic version of Teva Pharmaceutical's (TEVA +1%) ProAir HFA. The filing involves contributions from both PRGO and Catalent Pharma Solutions, who partnered on the development. TEVA claims the application violates its patent on the drug, and yesterday it filed suit against both companies in U.S. District Court alleging patent infringement. 1 Comment [On the Move, Healthcare]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Steffen Jørgensen
I just published an interesting article about $TEVA - A company in the pharmaceutical industry with low valuation and remarkable growth - View all 4 replies
-
onneke: be carefull, with teva , the goodwill is too high, if one deducts same, p/b ratio is 8....!! -
Steffen Jørgensen: and why do you think their goodwill is too high? What do you base your conclusion on?
-
Steffen Jørgensen
How much will $TEVA fall before the rebound starts? The current price has strong historical TA support. Fundamentals are strong as well - View all 0 replies
-
Dividend Sheet
$AZN $GSK $MRK are the best yielding heathcare stocks with a lower volatility than the market - http://stks.co/cP2U - $JNJ $TEVA - View all 0 replies
-
Contextuall
Media Sentiment on Teva Pharmaceutical Industries Limited $TEVA: 21.74% positive, 11.59% negative, 66.67% neutral http://bit.ly/ZXSUZR - View all 0 replies
-
- View all 6 replies
-
-
Steffen Jørgensen: Agree TDune75, but Teva is a long-term inv. due to growth in dividend, revenues and EPS. The domegraphic conditions looks good as well.
-
- View all 2 replies
-
charlot-97: I'll enjoy any uptrend in $TEVA that lasts longer than 15 minutes. Disclosure: Long $TEVA, sometimes unsure why. -
-
Retail Investor
$DNDN $AMRN $TEVA $ARNA $CLSN $SPY $TARO Posts Strong Results -> http://bit.ly/THNRyQ - View all 0 replies
LATEST REPLIES
-
Steffen Jørgensen
I just published an interesting article about $TEVA - A company in the pharmaceutical industry with low valuation and remarkable growth - View all 4 replies
-
onneke: be carefull, with teva , the goodwill is too high, if one deducts same, p/b ratio is 8....!!
-
Steffen Jørgensen: and why do you think their goodwill is too high? What do you base your conclusion on?
-
- View all 6 replies
-
-
Steffen Jørgensen: Agree TDune75, but Teva is a long-term inv. due to growth in dividend, revenues and EPS. The domegraphic conditions looks good as well.
-
- View all 2 replies
-
charlot-97: I'll enjoy any uptrend in $TEVA that lasts longer than 15 minutes. Disclosure: Long $TEVA, sometimes unsure why.
-
-
neobliviscar
$TEVA- closing personal position. Sold 40 Jan $37.5 puts for about 0.75 & buying back at 0.05. I know one or two others were in with me. - View all 2 replies
-
-
SKS1586: Awesome. I entered around same time by selling Jan14 50Puts (longer horizon & dividend collection). Your strategy looks better now.
-
- View all 4 replies
-
VFC's Stock House: Haha, SmokeyRose - I don't know much more than anyone else, except that $INO is up about twenty five percent this year. Nice. Good luck!
-
-
- View all 7 replies
-
-
Julius Ferraro: Sold some 37.5 puts. Nothing in this market is cheap anymore
-
neobliviscar
$TEVA . Had to wait for this one to bottom. Selling Jan Puts at this level. Be happy to go long here & conv to Cov Call later. - View all 5 replies
-
chopchop0: I decided to bite on a long position today. Seems insanely cheap at 7x forward earnings.
-
neobliviscar: P/E can be dang w/ drug co., but reviewing what they've got & the likelyhood of 'will have', seemed very safe risk/reward $35-$37.5 buy zone
-
Energysystems
Nice bounces for $MMLP, $KRFT, and $FCX. $TEVA is taking a big hit though...my only loser in my portfolio - View all 5 replies
-
Ocean Man: MMLP up 2% and absolutely no weakness as the market dropped late in the day.
-
-
Energysystems
Nice to see $AFL finally making me some $$. Now only one negative position in my portfolio($TEVA). - View all 1 replies
-
-
1980XLS-2.0
TEVA. It appears the banksters that bought tens of thousands of Oct $42.50 calls a week or two ago, plan on not being denied. - View all 5 replies
-
1980XLS-2.0: I played it mostly with stock, got out yeasterday,with modest gains, thanks to filling position incrementally.Somebody lost big.
-
FortSumter: Turns out they were expecting an FDA approval which came yesterday.....oops, a little late. haha
-
- View all 8 replies
-
-
FortSumter: Quick math shows 26K @100 shares per to tie up almost 3% of the available shares for a one day event. Hmmmmm.
-
- View all 3 replies
-
-
-
Saibus Research
Teva: Undervalued Industry Leading Generic Drug Maker At 7.5X Adjusted EPS http://seekingalpha.com/a/gx39 $TEVA - View all 2 replies
-
Mercy Jimenez: Agree but watch entry price; testing results, Israeli/ Iran jitters etc.have swung to $35 recently; I add as it hits $37-39 during meltdowns -
Saibus Research: Mercy, not a bad entry point. Healthcare sector undervalued relative to its historical multiples and has held up well in the last few months
-
Daniel Shvartsman
$TEVA wins Copaxone trial, up almost 7% AH. I'm bummed it never dropped to my limit orders at 37.5. Weird to drop good news late on Friday. - View all 1 replies
-
Energysystems: Hopefully it'll continue up a bit, looking to lighten up my position.
-
Mercy Jimenez
Sold back out TEVA addition from Fri; premarket action @$38 + continued high selling ratio does not look healthy; will add back on drops. - View all 6 replies
-
-